Persephoni Biopartners, a life sciences venture studio dedicated to supporting early-stage biotechnology startups, has expanded its C-Suite with the appointment of Donna Taraborelli as Chief Operating Officer (COO).
| BioBuzz’s mission is simple: to be more connected. Our regionally-focused storytelling, programs, events and experiences connect, amplify and create impact across the life science workforce in growing biohubs. Submit your People On The Move (free and ongoing) to showcase your company’s growth by promoting your new hires and recent promotions. |
With Dr. Taraborelli’s excellent leadership and varied skillset, she is equipped to help startups at all phases of development.
This appointment comes a month after Persephoni’s C-Suite establishment with CEO Hilary Schultz and CSO William Heath.
Persephoni CEO Hilary Schultz stated, “I am beyond excited to welcome Dr. Donna Taraborelli to the Persephoni BioPartners family as our new Chief Operating Officer. Donna’s extensive experience and leadership in the life sciences sector make her the ideal addition to our executive team. Her track record speaks for itself. I am confident that her strategic vision, operational excellence, and deep commitment to advancing healthcare innovation will be pivotal in guiding our continued growth and bringing therapies to patients.”
About Dr. Donna Taraborelli
Dr. Taraborelli holds a Doctor of Public Health from Harvard University and advanced degrees from Johns Hopkins University and the University of Pennsylvania. She previously worked as a Senior Director at Clearside Biomedical, where her contributions supported the company’s IPO and FDA approval for its first drug.
Dr. Taraborelli has also held roles at Alcon and Merck, pushing forward clinical development and R&D programs.
With over two decades of experience across clinical research, drug development, life science consulting, and executive leadership, Dr. Taraborelli is well-suited to enable Persephoni in driving budding innovation.
About Persephoni BioPartners
Persephoni BioPartners is a venture studio and strategic consulting firm that provides commercialization solutions to visionary life sciences researchers and early-stage biotechnology startups throughout the company’s lifecycle. Its venture studio model provides direct support services and guidance throughout all stages of business development and commercialization.
Persephoni utilizes its highly experienced network of entrepreneurs, industry experts, and investors to deliver tailored solutions across the spectrum of business needs, including company formation, IP & Tech Transfer, Capital Raise, Business Development, and R&D Strategy. Through venture, research, and pharma collaborations, they de-risk and accelerate the advancement of breakthrough technologies, enabling partners to have line of sight and the needed pressure testing on ideas. Persephoni allows founders to focus on scientific innovation while they enable teams dedicated to driving impactful change in the industry.
